益生菌补充对非酒精性脂肪性肝炎患者的影响:PROBILIVER 试验方案
本研究为双盲随机临床试验,纳入经活检确诊的非酒精性脂肪性肝炎成人门诊患者,比较益生菌混合制剂与安慰剂对肠道菌群调节、肝脂肪变与纤维化程度、炎症、肠道通透性及身体成分的影响。干预为每日2袋、持续24周,基线与24周时重复评估,研究结果计划于2020年分析发布。
要点
- 双盲随机对照试验,对象为活检确诊的非酒精性脂肪性肝炎成人门诊患者
- 益生菌混合制剂每株1×10^9 CFU,每日2袋,持续24周,对照为安慰剂
- 结局包括肠道菌群、肝脂肪变与纤维化、炎症、肠道通透性及身体成分
核心结论
- 原文为试验方案,未报告研究结果与结论。
研究设计与样本
- 双盲、随机临床试验,纳入经活检确诊的非酒精性脂肪性肝炎成人门诊患者,活检可联合或不联合瞬时弹性成像。
- 患者随机分配接受治疗A或治疗B,患者与参与研究者均设盲。
- 干预为益生菌混合制剂(嗜酸乳杆菌+动物双歧杆菌乳亚种+鼠李糖乳杆菌+副干酪乳杆菌,每株1×10^9 CFU)与特征及包装完全一致的安慰剂。
- 患者被指导每日服用2袋、持续24周,并报告与服用相关的任何症状或副作用。
- 依从性通过患者在所提供表格上的记录及核对已使用袋数进行控制。
主要发现
- 所有患者将接受完整病史采集,以调查饮酒情况、既往史、用药、营养评估(膳食摄入与身体成分)、肌少症、体力活动水平及身体与功能能力、心血管风险。
- 生化参数评估包括炎症状态、血脂谱、肝功能、肠道通透性及微生物群评估。
- 上述程序在基线进行,并在24周(研究结束时)重复。
临床怎么用
- 原文为研究方案,未据此给出临床推荐。
局限性
- 原文为试验方案,未报告研究结果,也未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently factors in the relationship between gut microbiota, obesity, diabetes and the metabolic syndrome have been suggested in the development and progression of nonalcoholic steatohepatitis (NASH). In this sense, this work aims to evaluate the effects of probiotic supplementation on intestinal microbiota modulation, degree of hepatic steatosis and fibrosis, inflammation, gut permeability, and body composition. METHODS: This double-blind, randomized clinical trial will include adult outpatients with a diagnosis of NASH confirmed by biopsy with or without transient elastography. All patients will undergo a complete anamnesis to investigate their alcohol consumption, previous history, medications, nutritional assessment (dietary intake and body composition), sarcopenia, physical activity level and physical and functional capacity, cardiovascular risk, biochemical parameters for assessment of inflammatory status, lipid profile, hepatic function, gut permeability, and assessment of microbiota. These procedures will be performed at baseline and repeated after 24 weeks (at the end of the study). Through the process of randomization, patients will be allocated to receive treatment A or treatment B. Both patients and researchers involved will be blinded (double-blind study). The intervention consists of treatment with a probiotic mix (Lactobacillus acidophillus + Bifidobacterium lactis + Lactobacillus rhamnosus + Lactobacillus paracasei, 1 x 109 CFU for each) and the placebo which is identical in all its characteristics and packaging. Patients will be instructed to consume two sachets/day during 24 weeks and to report any symptoms or side effects related to the use of the sachets. Adherence control will be carried out through the patient's notes on a form provided, and also by checking the number of sachets used. DISCUSSION: The final results of study will be analyzed and disseminated in 2020. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03467282 . Registered on 15 March 2018.
引用
- Silva-Sperb AS, Moraes HA, de Moura BC, et al. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. Trials. 2019. PMID: 31601229. doi:10.1186/s13063-019-3679-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。